Experience

LifeArc

• United Kingdom
• Non-profit Organizations
• 200 - 300 Employee

• Member Board Of Trustees

  • Jul 2016 - Present



Les Hughes Consultancy

• Consultant

  • 2011 - Present



AstraZeneca R&D

• Global VP Cancer and Infection Research at AstraZeneca

  • 1999 - 2011

  As part of the Senior Management Team for AZ Discovery Delivered strategies and plans for Compound Management, High Throughput Screening, chemical supply and Translational Science resulting in AZ investment of >$50M Developed strategy review for R&D in 2007 that evolved into the major changes enacted by AZ in 2009 Delivered competitive research strategies for both Oncology and Infection disease areas encompassing small and large molecules. Delivered 55 compounds into… Show more As part of the Senior Management Team for AZ Discovery Delivered strategies and plans for Compound Management, High Throughput Screening, chemical supply and Translational Science resulting in AZ investment of >$50M Developed strategy review for R&D in 2007 that evolved into the major changes enacted by AZ in 2009 Delivered competitive research strategies for both Oncology and Infection disease areas encompassing small and large molecules. Delivered 55 compounds into pre-clinical development over the past 10 years while building the group to its current capacity. 24 of these compounds have already progressed to clinical trial with 11 passing into Phase II and 1 in regulatory review. Built groups in Boston (Infection 45-180 and Cancer 0-150) that have already delivered 18 compounds into pre-clinical development Built group in Shanghai to deliver the science to support our portfolio of products in Asian patients. Delivered value through Personalised approach for Iressa (sales in excess of $100M in China) as well as initiating trials in Gastric and Hepatocellular Cancer. In 2005 incorporated Bangalore group into Global Infection group which enabled the first AZ compound for treatment of tuberculosis (TB) to be delivered in 2009 and connected group to global TB network to ensure the compound will be taken rapidly into clinical trial. Managed the acquired small Biotech companies Arrow and Kudos to ensure that they benefited from the capabilities in AZ but we learnt from their entrepreneurial spirit; outcome was not only the delivery of higher quality compounds into development but I used the experience of Kudos to push an AZ compound into development more rapidly Participated in overall Disease Strategy for AZ agreed with the business to include delivery of portfolio of products throughout the value chain Managed portfolio of compounds in clinical development, initially up to and including Life Cycle Management, making initial decisions on plans and priorities Show less As part of the Senior Management Team for AZ Discovery Delivered strategies and plans for Compound Management, High Throughput Screening, chemical supply and Translational Science resulting in AZ investment of >$50M Developed strategy review for R&D in 2007 that evolved into the major changes enacted by AZ in 2009 Delivered competitive research strategies for both Oncology and Infection disease areas encompassing small and large molecules. Delivered 55 compounds into… Show more As part of the Senior Management Team for AZ Discovery Delivered strategies and plans for Compound Management, High Throughput Screening, chemical supply and Translational Science resulting in AZ investment of >$50M Developed strategy review for R&D in 2007 that evolved into the major changes enacted by AZ in 2009 Delivered competitive research strategies for both Oncology and Infection disease areas encompassing small and large molecules. Delivered 55 compounds into pre-clinical development over the past 10 years while building the group to its current capacity. 24 of these compounds have already progressed to clinical trial with 11 passing into Phase II and 1 in regulatory review. Built groups in Boston (Infection 45-180 and Cancer 0-150) that have already delivered 18 compounds into pre-clinical development Built group in Shanghai to deliver the science to support our portfolio of products in Asian patients. Delivered value through Personalised approach for Iressa (sales in excess of $100M in China) as well as initiating trials in Gastric and Hepatocellular Cancer. In 2005 incorporated Bangalore group into Global Infection group which enabled the first AZ compound for treatment of tuberculosis (TB) to be delivered in 2009 and connected group to global TB network to ensure the compound will be taken rapidly into clinical trial. Managed the acquired small Biotech companies Arrow and Kudos to ensure that they benefited from the capabilities in AZ but we learnt from their entrepreneurial spirit; outcome was not only the delivery of higher quality compounds into development but I used the experience of Kudos to push an AZ compound into development more rapidly Participated in overall Disease Strategy for AZ agreed with the business to include delivery of portfolio of products throughout the value chain Managed portfolio of compounds in clinical development, initially up to and including Life Cycle Management, making initial decisions on plans and priorities Show less